Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2013

Open Access 01-10-2013 | Research

Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study

Authors: Christian Fynbo Christiansen, Martin Berg Johansen, Steffen Christensen, James M O’Brien, Else Tønnesen, Henrik Toft Sørensen

Published in: Critical Care | Issue 5/2013

Login to get access

Abstract

Introduction

Metformin has anti-inflammatory and anti-thrombotic effects that may improve the outcome of critical illness, but clinical data are limited. We examined the impact of preadmission metformin use on mortality among intensive care unit (ICU) patients with type 2 diabetes.

Methods

We conducted this population-based cohort study among all persons admitted to the 17 ICUs in Northern Denmark (population approximately 1.8 million). We focused on all patients with type 2 diabetes who were admitted to the ICUs between January 2005 and December 2011. Through individual-level linkage of population-based medical databases, type 2 diabetes was identified using a previously validated algorithm including hospital diagnoses, filled prescriptions for anti-diabetic drugs, and elevated HbA1c levels. Metformin use was identified by filled prescriptions within 90 days before admission. Covariates included surgery, preadmission morbidity, diabetes duration, and concurrent drug use. We computed 30-day mortality and hazard ratios (HRs) of death using Cox regression adjusted for covariates, both overall and after propensity score matching.

Results

We included 7,404 adult type 2 diabetes patients, representing 14.0% of 52,964 adult patients admitted to the ICUs. Among type 2 diabetes patients, 1,073 (14.5%) filled a prescription for metformin as monotherapy within 90 days before admission and 1,335 (18.0%) received metformin in combination with other anti-diabetic drugs. Thirty-day mortality was 17.6% among metformin monotherapy users, 17.9% among metformin combination therapy users, and 25.0% among metformin non-users. The adjusted HRs were 0.80 (95% confidence interval (CI): 0.69, 0.94) for metformin monotherapy users and 0.83 (95% CI: 0.71, 0.95) for metformin combination therapy users, compared to non-users. Propensity-score-matched analyses yielded the same results. The association was evident across most subgroups of medical and surgical ICU patients, but most pronounced in elderly patients and in patients with well-controlled diabetes. Former metformin use was not associated with decreased mortality.

Conclusions

Preadmission metformin use was associated with reduced 30-day mortality among medical and surgical intensive care patients with type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
2.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32: 193-203. 10.2337/dc08-9025PubMedCentralCrossRefPubMed
3.
Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 2002, 137: 25-33. 10.7326/0003-4819-137-1-200207020-00009CrossRefPubMed
4.
Prospective UK, Diabetes Study (UKPDS) group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 854-865.CrossRef
5.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359: 1577-1589. 10.1056/NEJMoa0806470CrossRefPubMed
6.
Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008, 168: 2070-2080. 10.1001/archinte.168.19.2070PubMedCentralCrossRefPubMed
7.
Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE: Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011, 60: 1-23. 10.1016/j.metabol.2010.09.010PubMedCentralCrossRefPubMed
8.
Hundal RS, Inzucchi SE: Metformin: new understandings, new uses. Drugs 2003, 63: 1879-1894. 10.2165/00003495-200363180-00001CrossRefPubMed
9.
Tsoyi K, Jang HJ, Nizamutdinova IT, Kim YM, Lee YS, Kim HJ, Seo HG, Lee JH, Chang KC: Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol 2011, 162: 1498-1508. 10.1111/j.1476-5381.2010.01126.xPubMedCentralCrossRefPubMed
10.
Grant PJ: Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003, 29: 6S44-6S52.CrossRefPubMed
11.
Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Siegal GP, Abraham E: Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008, 178: 168-179. 10.1164/rccm.200710-1602OCPubMedCentralCrossRefPubMed
12.
Ansari G, Mojtahedzadeh M, Kajbaf F, Najafi A, Khajavi MR, Khalili H, Rouini MR, Ahmadi H, Abdollahi M: How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008, 25: 681-702. 10.1007/s12325-008-0075-1CrossRefPubMed
13.
Duncan AI, Koch CG, Xu M, Manlapaz M, Batdorf B, Pitas G, Starr N: Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg 2007, 104: 42-50. 10.1213/01.ane.0000242532.42656.e7CrossRefPubMed
14.
Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008, 29: 166-176.CrossRefPubMed
15.
Horsdal HT, Johnsen SP, Sondergaard F, Rungby J: Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008, 51: 567-574. 10.1007/s00125-008-0947-6CrossRefPubMed
16.
Lamanna C, Monami M, Marchionni N, Mannucci E: Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011, 13: 221-228. 10.1111/j.1463-1326.2010.01349.xCrossRefPubMed
17.
Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348: 138-150. 10.1056/NEJMra021333CrossRefPubMed
18.
Toft P, Tonnesen E: Immune-modulating interventions in critically ill septic patients: pharmacological options. Expert Rev Clin Pharmacol 2011, 4: 491-501. 10.1586/ecp.11.25CrossRefPubMed
19.
Christiansen CF, Johansen MB, Christensen S, O’Brien JM, Tonnesen E, Sorensen HT: Type 2 diabetes and 1-year mortality in intensive care unit patients. Eur J Clin Invest 2012, 43: 238-247.CrossRefPubMed
20.
Pedersen CB, Gotzsche H, Moller JO, Mortensen PB: The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006, 53: 441-449.PubMed
21.
22.
Frank L: Epidemiology, When an entire country is a cohort. Science 2000, 287: 2398-2399. 10.1126/science.287.5462.2398CrossRefPubMed
23.
Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH: The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46: 263-268.PubMed
24.
Christiansen CF, Christensen S, Johansen MB, Larsen KM, Tonnesen E, Sorensen HT: The impact of pre-admission morbidity level on 3-year mortality after intensive care: a Danish cohort study. Acta Anaesthesiol Scand 2011, 55: 962-970.PubMed
25.
Blichert-Hansen L, Nielsson MS, Nielsen RB, Christiansen CF, Norgaard M: Validity of the coding for intensive care admission, mechanical ventilation, and acute dialysis in the Danish National Patient Registry: a short report. Clin Epidemiol 2013, 5: 9-12.PubMedCentralPubMed
26.
Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT: Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007, 30: 2251-2257. 10.2337/dc06-2417CrossRefPubMed
27.
Ehrenstein V, Antonsen S, Pedersen L: Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010, 2: 273-279.PubMedCentralCrossRefPubMed
28.
Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW: Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol 2011, 3: 133-138.PubMedCentralCrossRefPubMed
29.
Horsdal HT, Sondergaard F, Johnsen SP, Rungby J: Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study. Pharmacoepidemiol Drug Saf 2011, 20: 331-337. 10.1002/pds.2097CrossRefPubMed
30.
Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158: 915-920. 10.1093/aje/kwg231CrossRefPubMed
31.
Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL: Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001, 286: 1754-1758. 10.1001/jama.286.14.1754CrossRefPubMed
32.
Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011, 11: 83. 10.1186/1471-2288-11-83PubMedCentralCrossRefPubMed
33.
Christensen S, Thomsen RW, Johansen MB, Pedersen L, Jensen R, Larsen KM, Larsson A, Tonnesen E, Sorensen HT: Preadmission statin use and one-year mortality among patients in intensive care - a cohort study. Crit Care 2010, 14: R29. 10.1186/cc8902PubMedCentralCrossRefPubMed
34.
Christensen S, Johansen MB, Tonnesen E, Larsson A, Pedersen L, Lemeshow S, Sorensen HT: Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit Care 2011, 15: R87. 10.1186/cc10085PubMedCentralCrossRefPubMed
35.
Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Losche W: Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010, 38: 32-37. 10.1097/CCM.0b013e3181b4275cCrossRefPubMed
36.
Gammelager H, Christiansen CF, Johansen MB, Tonnesen E, Jespersen B, Sorensen HT: One-year mortality among Danish intensive care patients with acute kidney injury: a cohort study. Crit Care 2012, 16: R124. 10.1186/cc11420PubMedCentralCrossRefPubMed
37.
Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270: 2957-2963. 10.1001/jama.1993.03510240069035CrossRefPubMed
38.
Schisterman EF, Cole SR, Platt RW: Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009, 20: 488-495. 10.1097/EDE.0b013e3181a819a1PubMedCentralCrossRefPubMed
39.
Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98: 253-259. 10.1111/j.1742-7843.2006.pto_293.xPubMedCentralCrossRefPubMed
40.
Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S: A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006, 59: 437-447.PubMedCentralPubMed
41.
Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ: Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001, 54: 387-398. 10.1016/S0895-4356(00)00321-8CrossRefPubMed
42.
Austin PC: Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007, 134: 1128-1135. 10.1016/j.jtcvs.2007.07.021CrossRefPubMed
43.
Horsdal HT, Ulrichsen SP, Thomsen RW, Norgaard M, Larsen FB, Sorensen HT: Lifestyle Profile among Users of Antidiabetic Treatments [abstract]. Pharmacoepidemiol Drug Saf 2011, 20: S292. 10.1002/pds.2051CrossRef
44.
Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH: Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002, 162: 434-437. 10.1001/archinte.162.4.434CrossRefPubMed
45.
Lipska KJ, Bailey CJ, Inzucchi SE: Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34: 1431-1437. 10.2337/dc10-2361PubMedCentralCrossRefPubMed
46.
Oliveros H, Villamor E: Obesity and mortality in critically ill adults: a systematic review and meta-analysis. Obesity (Silver Spring) 2008, 16: 515-521. 10.1038/oby.2007.102CrossRef
47.
O’Brien JM Jr, Philips GS, Ali NA, Aberegg SK, Marsh CB, Lemeshow S: The association between body mass index, processes of care, and outcomes from mechanical ventilation: a prospective cohort study. Crit Care Med 2012, 40: 1456-1463. 10.1097/CCM.0b013e31823e9a80CrossRefPubMed
48.
Seidowsky A, Nseir S, Houdret N, Fourrier F: Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009, 37: 2191-2196. 10.1097/CCM.0b013e3181a02490CrossRefPubMed
49.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, CD002967.
Metadata
Title
Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study
Authors
Christian Fynbo Christiansen
Martin Berg Johansen
Steffen Christensen
James M O’Brien
Else Tønnesen
Henrik Toft Sørensen
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2013
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc12886

Other articles of this Issue 5/2013

Critical Care 5/2013 Go to the issue

Letter

The 372 T/C genetic polymorphism of TIMP-1 as a biomarker of mortality in patients with sepsis

Research

Better lactate clearance associated with good neurologic outcome in survivors who treated with therapeutic hypothermia after out-of-hospital cardiac arrest

Commentary

Should hydroxyethyl starch solutions be totally banned?

Research

Pleural ultrasonography versus chest radiography for the diagnosis of pneumothorax: review of the literature and meta-analysis

Research

Suspected ventilator-associated respiratory infection in severely ill patients: a prospective observational study

Research

Epidemiology of critically ill patients in intensive care units: a population-based observational study